Britain and America have forged a major bilateral deal that will preserve zero tariffs on UK medicine shipments going into the US market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to raise expenditure on medicines through the public health system. This pledge ensures that import taxes on these key goods will remain at nothing for a period of three years.
This agreement comes after recent threats to significantly raise tariffs on patented pharmaceutical imports, with figures mentioned up to double the cost.
"This arrangement with the Britain bolsters the global environment for cutting-edge drugs and brings much-needed balance to American-British medicine commerce," an announcement said.
Commercial Importance
Pharmaceuticals represent one of the UK's largest goods shipped to the America, which is by far the largest market for leading British pharmaceutical firms.
Statistics show that in the 12 months leading up to last September, the UK sold drugs worth £11.1bn to the US. This amount represented nearly one-fifth of total UK exports in that period.
"This guarantee protects work, boosts capital expenditure and sets the stage for the UK to establish itself as a global hub for medical research," a government official stated.
Key NHS Changes
The agreement entails several specific changes from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a target to increase total public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The amount pharmaceutical firms must return to the NHS to control costs will be restricted at fifteen percent. Previously, refunds were more than 20%.
Industry Background
The deal follows a ongoing tension between the drug companies and the British authorities over medicine costs and approval rates.
These tensions were heightened by assertions that American customers were charged several times more for the identical medicines than patients in the other developed nations.
In recent months, several major manufacturing plans in the UK have been halted or scrapped, while substantial expansions have been announced toward projects in the United States.
The Science Minister stated that the NHS had to invest a greater share on drugs, noting that its spending on drugs had declined as a proportion of its overall budget over the past decade.
